Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine praxisnahe, multizentrische, prospektive Beobachtungsstudie für PNH in China (ReWoPNH)

22. September 2026 aktualisiert von: AstraZeneca

Eine praxisnahe, multizentrische, prospektive Beobachtungsstudie zur paroxysmalen nächtlichen Hämoglobinurie (PNH) in China

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Detaillierte Beschreibung

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

724

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Hangzhou, China
        • Research Site
    • Anhui
      • Hefei, Anhui, China, 230002
        • Research Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100000
        • Research Site
      • Beijing, Beijing Municipality, China, 100044
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, China, 510080
        • Research Site
      • Guangzhou, Guangdong, China, 510180
        • Research Site
      • Guangzhou, Guangdong, China, 510515
        • Research Site
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • Research Site
    • Guizhou
      • Guiyang, Guizhou, China, 550004
        • Research Site
    • Hebei
      • Shijiazhuang, Hebei, China, 050000
        • Research Site
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150001
        • Research Site
    • Henan
      • Zhengzhou, Henan, China, 450003
        • Research Site
      • Zhengzhou, Henan, China, 450052
        • Research Site
      • Zhengzhou, Henan, China, 463599
        • Research Site
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Research Site
      • Wuhan, Hubei, China, 430000
        • Research Site
    • Hunan
      • Changsha, Hunan, China, 410008
        • Research Site
      • Changsha, Hunan, China, 410005
        • Research Site
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Research Site
      • Nantong, Jiangsu, China, 226001
        • Research Site
      • Xuzhou, Jiangsu, China, 221002
        • Research Site
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Research Site
      • Nanchang, Jiangxi, China, 330008
        • Research Site
    • Jilin
      • Changchun, Jilin, China, 130021
        • Research Site
    • Liaoning
      • Shenyang, Liaoning, China, 110001
        • Research Site
    • Shandong
      • Jinan, Shandong, China, 250000
        • Research Site
      • Qingdao, Shandong, China, 266000
        • Research Site
      • Zibo, Shandong, China, 255090
        • Research Site
    • Shangdong
      • Linyi, Shangdong, China, 276034
        • Research Site
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200040
        • Research Site
      • Shanghai, Shanghai Municipality, China, 200336
        • Research Site
    • Shanxi
      • Taiyuan, Shanxi, China, 030000
        • Research Site
      • Xi’an, Shanxi, China, 710061
        • Research Site
      • Xi’an, Shanxi, China, 710068
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Research Site
      • Chengdu, Sichuan, China, 610072
        • Research Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300020
        • Research Site
      • Tianjin, Tianjin Municipality, China, 300052
        • Research Site
      • Tianjin, Tianjin Municipality, China, 300190
        • Research Site
    • Yunnan
      • Kunming, Yunnan, China, 650034
        • Research Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Beschreibung

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Zeitfenster: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
Zeitfenster: 12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
Zeitfenster: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
Zeitfenster: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
Zeitfenster: 12 months

To characterize the progression of PNH

12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number and percentage of patients with each symptom of interest within follow-up
Zeitfenster: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
Zeitfenster: baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Zeitfenster: 12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Zeitfenster: 12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
Zeitfenster: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
Zeitfenster: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
Zeitfenster: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
Zeitfenster: 12 months

To describe clinical characteristics of patients with PNH in China

12 months

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Zeitfenster: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Zeitfenster: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
Zeitfenster: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Zeitfenster: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Zeitfenster: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

10. November 2023

Primärer Abschluss (Tatsächlich)

3. Dezember 2025

Studienabschluss (Tatsächlich)

3. Dezember 2025

Studienanmeldedaten

Zuerst eingereicht

30. Oktober 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. November 2023

Zuerst gepostet (Tatsächlich)

4. Dezember 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

24. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • D7414R00001

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD-Sharing-Zeitrahmen

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-Sharing-Zugriffskriterien

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .